Literature DB >> 22033920

Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover.

Jun Hee Lim1, Yu Liu, Erin Reineke, Hung-Ying Kao.   

Abstract

The promyelocytic leukemia (PML) protein is a tumor suppressor that has an important role in several cellular processes, including apoptosis, viral infection, DNA damage repair, cell cycle regulation, and senescence. PML is an essential component of sub-nuclear structures called PML nuclear bodies (NBs). Our laboratory has previously demonstrated that the peptidyl-prolyl cis-trans isomerase, Pin1, binds and targets PML for degradation in a phosphorylation-dependent manner. To further elucidate the mechanisms underlying Pin1-mediated PML degradation, we aimed to identify one or more factors that promote PML phosphorylation. Here we show that treatment with U0126, an inhibitor of the ERK2 upstream kinases MEK1/2, leads to an increase in PML protein accumulation and an inhibition of the interaction between Pin1 and PML in MDA-MB-231 breast cancer cells. Consistent with this observation, phosphorylated ERK2 partially co-localized with PML NBs. Although U0126 up-regulated exogenous wild-type PML levels, it did not have an effect on the steady-state level of a mutant form of PML that is defective in binding Pin1. In addition, exogenous wild-type, but not Pin1 binding-defective PML protein expression levels were decreased by overexpression of ERK2. In contrast, knockdown of ERK2 by siRNA resulted in an increase in PML protein levels and an increase in the formation of PML NBs. Using phospho-specific antibodies, we identified Ser-403 and Ser-505 as the ERK2 targets that promote Pin1-mediated PML degradation. Finally, we demonstrated that EGF induced activation of ERK and interaction between PML and phosphorylated ERK resulting in a decrease in PML protein levels. Taken together, our results support a model in which Pin1 promotes PML degradation in an ERK2-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22033920      PMCID: PMC3248013          DOI: 10.1074/jbc.M111.289512

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

Review 1.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

Review 2.  Review: properties and assembly mechanisms of ND10, PML bodies, or PODs.

Authors:  G G Maul; D Negorev; P Bell; A M Ishov
Journal:  J Struct Biol       Date:  2000-04       Impact factor: 2.867

3.  Role of PML in cell growth and the retinoic acid pathway.

Authors:  Z G Wang; L Delva; M Gaboli; R Rivi; M Giorgio; C Cordon-Cardo; F Grosveld; P P Pandolfi
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

4.  A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression.

Authors:  Wei-Chien Yuan; Yu-Ru Lee; Shiu-Feng Huang; Yu-Min Lin; Tzu-Yin Chen; Hsiang-Ching Chung; Chin-Hsien Tsai; Hsin-Yi Chen; Cheng-Ta Chiang; Chun-Kai Lai; Li-Ting Lu; Chun-Hau Chen; De-Leung Gu; Yeong-Shiau Pu; Yuh-Shan Jou; Kun Ping Lu; Pei-Wen Hsiao; Hsiu-Ming Shih; Ruey-Hwa Chen
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

Review 5.  The Ras-ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies.

Authors:  Fernando Calvo; Lorena Agudo-Ibáñez; Piero Crespo
Journal:  Bioessays       Date:  2010-05       Impact factor: 4.345

6.  Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis.

Authors:  Fumihiko Hayakawa; Martin L Privalsky
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

7.  RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.

Authors:  Michael H Tatham; Marie-Claude Geoffroy; Linnan Shen; Anna Plechanovova; Neil Hattersley; Ellis G Jaffray; Jorma J Palvimo; Ronald T Hay
Journal:  Nat Cell Biol       Date:  2008-04-13       Impact factor: 28.824

Review 8.  New insights into the role of PML in tumour suppression.

Authors:  P Salomoni; B J Ferguson; A H Wyllie; T Rich
Journal:  Cell Res       Date:  2008-06       Impact factor: 25.617

9.  Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1.

Authors:  Erin L Reineke; Yu Liu; Hung-Ying Kao
Journal:  J Biol Chem       Date:  2010-01-25       Impact factor: 5.157

10.  Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.

Authors:  V Lallemand-Breitenbach; J Zhu; F Puvion; M Koken; N Honoré; A Doubeikovsky; E Duprez; P P Pandolfi; E Puvion; P Freemont; H de Thé
Journal:  J Exp Med       Date:  2001-06-18       Impact factor: 14.307

View more
  20 in total

Review 1.  Prolyl isomerase Pin1 in cancer.

Authors:  Zhimin Lu; Tony Hunter
Journal:  Cell Res       Date:  2014-08-15       Impact factor: 25.617

2.  Ablation of promyelocytic leukemia protein (PML) re-patterns energy balance and protects mice from obesity induced by a Western diet.

Authors:  Xiwen Cheng; Shuang Guo; Yu Liu; Hao Chu; Parvin Hakimi; Nathan A Berger; Richard W Hanson; Hung-Ying Kao
Journal:  J Biol Chem       Date:  2013-08-28       Impact factor: 5.157

3.  The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein.

Authors:  D Guan; D Factor; Yu Liu; Z Wang; H-Y Kao
Journal:  Oncogene       Date:  2012-09-03       Impact factor: 9.867

Review 4.  The role of PML ubiquitination in human malignancies.

Authors:  Ruey-Hwa Chen; Yu-Ru Lee; Wei-Chien Yuan
Journal:  J Biomed Sci       Date:  2012-08-30       Impact factor: 8.410

5.  Regulation of the tumor suppressor PML by sequential post-translational modifications.

Authors:  M Lienhard Schmitz; Inna Grishina
Journal:  Front Oncol       Date:  2012-12-31       Impact factor: 6.244

6.  Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer.

Authors:  Y-H Nicole Tsang; X-W Wu; J-S Lim; C Wee Ong; M Salto-Tellez; K Ito; Y Ito; L-F Chen
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

7.  PMA-induced dissociation of Ku86 from the promoter causes transcriptional up-regulation of histamine H(1) receptor.

Authors:  Hiroyuki Mizuguchi; Kohei Miyagi; Takuma Terao; Noriko Sakamoto; Yosuke Yamawaki; Tsubasa Adachi; Shohei Ono; Yohei Sasaki; Yoshiyuki Yoshimura; Yoshiaki Kitamura; Noriaki Takeda; Hiroyuki Fukui
Journal:  Sci Rep       Date:  2012-12-03       Impact factor: 4.379

8.  Differential Roles of PML Isoforms.

Authors:  Sébastien Nisole; Mohamed Ali Maroui; Xavier H Mascle; Muriel Aubry; Mounira K Chelbi-Alix
Journal:  Front Oncol       Date:  2013-05-22       Impact factor: 6.244

9.  New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers.

Authors:  Kamil Wolyniec; Dennis A Carney; Sue Haupt; Ygal Haupt
Journal:  Front Oncol       Date:  2013-05-17       Impact factor: 6.244

10.  PML Degradation: Multiple Ways to Eliminate PML.

Authors:  Andrea Rabellino; Pier Paolo Scaglioni
Journal:  Front Oncol       Date:  2013-03-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.